{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:55:11Z","timestamp":1786985711739,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["onlinejcf.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cardfail.2024.04.024","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T12:19:14Z","timestamp":1716207554000},"page":"1136-1153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"30","author":[{"given":"Lusha W.","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5154-0221","authenticated-orcid":false,"given":"Heidi S.","family":"Lumish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo R.","family":"Sewanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi J.","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shepard D.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8351-9219","authenticated-orcid":false,"given":"Kevin J.","family":"Clerkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2024.04.024_bib0001","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0002","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0003","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0004","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12872-020-01807-4","article-title":"Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy","volume":"20","author":"Velicki","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12265-009-9131-8","article-title":"Mechanical and energetic consequences of HCM-causing mutations","volume":"2","author":"Ferrantini","year":"2009","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0006","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1161\/CIRCULATIONAHA.108.838672","article-title":"Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction","volume":"119","author":"van Dijk","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCRESAHA.116.308830","article-title":"The Case of \"Missing Causal Genes\" and the Practice of Medicine: A Sherlock Holmes Approach of Deductive Reasoning","volume":"119","author":"Marian","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0008","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical Course and Management of Hypertrophic Cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0009","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0011","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0012","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2016.01.071","article-title":"The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context","volume":"67","author":"Sherrid","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0013","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0014","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.CIR.35.5.847","article-title":"Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade","volume":"35","author":"Cohen","year":"1967","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/hrt.32.6.804","article-title":"Long-term propranolol therapy in muscular subaortic stenosis","volume":"32","author":"Adelman","year":"1970","journal-title":"Br Heart J"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0016","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199703133361107","article-title":"The management of hypertrophic cardiomyopathy","volume":"336","author":"Spirito","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0017","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0002-9149(73)90012-X","article-title":"Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy","volume":"31","author":"Stenson","year":"1973","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0018","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","article-title":"beta Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy","volume":"110","author":"Nistri","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0019","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0020","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0021","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.CIR.64.4.787","article-title":"Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy","volume":"64","author":"Bonow","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0022","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/01.CIR.72.4.853","article-title":"Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects","volume":"72","author":"Bonow","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0023","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/01.CIR.79.5.1052","article-title":"Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy","volume":"79","author":"Udelson","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0024","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.60.6.1208","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0025","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1536\/ihj.27.701","article-title":"Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study","volume":"27","author":"Toshima","year":"1986","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0026","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0027","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005152","article-title":"Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients","volume":"6","author":"Adler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0029","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024656","article-title":"Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter","volume":"11","author":"Masri","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0030","first-page":"369","article-title":"Mavacamten for hypertrophic cardiomyopathy: effectiveness and value","volume":"28","author":"Beinfeld","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0031","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jtcvs.2018.11.148","article-title":"Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center","volume":"157","author":"Hodges","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0032","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0033","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0034","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jtcvs.2018.04.082","article-title":"Does septal myectomy reduce risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?","volume":"156","author":"Schaff","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0035","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.athoracsur.2012.06.008","article-title":"Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy","volume":"94","author":"Balaram","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0036","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/acs.2017.07.07","article-title":"Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience","volume":"6","author":"Rastegar","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0037","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003-2011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0038","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.echo.2018.10.011","article-title":"Accuracy of Jet Direction on Doppler Echocardiography in Identifying the Etiology of Mitral Regurgitation in Obstructive Hypertrophic Cardiomyopathy","volume":"32","author":"Hang","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0039","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7293","article-title":"Association of Septal Myectomy With Quality of Life in Patients With Left Ventricular Outflow Tract Obstruction From Hypertrophic Cardiomyopathy","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0040","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.athoracsur.2004.05.063","article-title":"Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy","volume":"78","author":"Deb","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0041","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.athoracsur.2007.07.063","article-title":"Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy","volume":"85","author":"Smedira","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0042","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007673","article-title":"Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes","volume":"12","author":"Kimmelstiel","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0043","doi-asserted-by":"crossref","first-page":"E58","DOI":"10.1002\/ccd.24328","article-title":"Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"81","author":"Sorajja","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0044","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","article-title":"Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy","volume":"72","author":"Batzner","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0045","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jtcvs.2018.08.062","article-title":"Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score-matched cohort","volume":"157","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0046","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jacc.2022.02.032","article-title":"Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy","volume":"79","author":"Cui","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0047","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.jacc.2011.09.020","article-title":"Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children","volume":"58","author":"Sreeram","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0048","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012106","article-title":"Transcatheter Myotomy to Treat Hypertrophic Cardiomyopathy and Enable Transcatheter Mitral Valve Replacement: First-in-Human Report of Septal Scoring Along the Midline Endocardium","volume":"15","author":"Greenbaum","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0049","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.cardfail.2024.04.024_bib0050","doi-asserted-by":"crossref","first-page":"9599","DOI":"10.3390\/ijms21249599","article-title":"Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases","volume":"21","author":"Alsulami","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0051","doi-asserted-by":"crossref","first-page":"E7486","DOI":"10.1073\/pnas.1720342115","article-title":"Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin","volume":"115","author":"Rohde","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0052","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0053","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168407","article-title":"A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0055","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0056","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0057","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0058","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0059","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0060","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): Health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0061","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0735-1097(21)01891-X","article-title":"Long-term Safety of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy: Interim Results of the MAVA-Long Term Extension (LTE) Study","volume":"77","author":"Rader","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0062","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0063","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamacardio.2019.4638","article-title":"Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy","volume":"5","author":"Eberly","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0064","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0065","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0066","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/CIRCULATIONAHA.120.051330","article-title":"Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective","volume":"143","author":"Maron","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0067","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0068","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cardfail.2023.07.003","article-title":"Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3","volume":"29","author":"Owens","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0069","article-title":"REDWOOD-HCM OLE: Aficamten in HCM","author":"Masri","year":"2022","journal-title":"European Society of Cardiology"},{"key":"10.1016\/j.cardfail.2024.04.024_bib0070","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424001830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424001830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T17:31:34Z","timestamp":1726594294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916424001830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1071916424001830"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.04.024","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}